Bioxodes SA, a clinical-stage biopharmaceutical company developing innovative therapies for thrombotic and inflammatory diseases, secured €5.5 million in a Series A extension to advance preparations for a potentially registrational Phase 2b trial of lead candidate BIOX-101 for intracerebral hemorrhage (ICH) in 2027. The round brought total Series A financing to approximately €17.5 million, with Newton Biocapital joining as a new investor alongside other new and existing shareholders. “Bioxodes is grateful for the renewed trust in the company’s ability to develop our groundbreaking treatment for hemorrhagic stroke. Our Phase 2a data clinical results in ICH patients are very promising and the principal investigator is encouraging us to push forward rapidly with registrational studies. I am particularly excited to see the respected specialist fund, Newton Biocapital, join our group of shareholders. The funding advances preparations for the pivotal Phase 2b trial and may enable us to bring BIOX-101 to patients as early as the second half of 2030,” said Marc Dechamps, CEO at Bioxodes.
Bioxodes recently reported strong interim findings from the BIRCH Phase 2a trial in ICH, meeting the safety endpoint and showing meaningful efficacy signals in clinical and biomarker measures, leading the DMC to recommend moving into a larger Phase 2b study. Launching the trial in 2027 could position BIOX-101 for conditional marketing submissions in the U.S. by late 2030 and in Europe by early 2031. Bioxodes also plans to extend BIOX-101 development into ischemic stroke and has opened an €80 million Series B round while engaging potential strategic partners. “Bioxodes looks to be a rare example of a success story in stroke. The BIOX-101 Phase 2a trial yielded very convincing data in intracerebral hemorrhage, an often deadly disease that presents an important unmet medical need. While the company is breaking new ground in this indication, we believe the path to registration is clear, with objective endpoints that look achievable based on the data at hand. BIOX-101 is exactly the kind of innovative drug that we at Newton like to have in our portfolio, also given our previous experience supporting companies in neurological and neurovascular diseases, including stroke,” said Alain Parthoens, Chief Executive Officer at Newton Biocapital.
ICH remains a highly lethal condition, representing up to 40% of stroke-related deaths despite accounting for just 15% of strokes. Mortality approaches 50% within 30 days, with significant long-term disability among survivors due to secondary ischemia, neuroinflammation, and neuronal damage. Existing anticoagulants cannot be used because of bleeding risks, while BIOX-101 is the first-in-class candidate demonstrating anticoagulant activity without increasing bleeding. The molecule also offers potent anti-inflammatory effects through neutrophil modulation, presenting a dual mechanism aimed at improving survival and recovery for ICH patients.